日本人群中伴CFTR变异的肺非结核分枝杆菌病的临床特征
本研究分析了2016年2月至2019年3月在庆应义塾大学医院就诊的458例肺非结核分枝杆菌病和(或)非囊性纤维化支气管扩张症患者,采用外显子测序、Sanger测序和MLPA检测CFTR变异。16例(3.5%)检出有害CFTR变异,均为单等位基因变异;与1:8年龄性别匹配的对照相比,这些患者痰培养转阴率更低、大环内酯类耐药率更高。一个家系中患肺非结核分枝杆菌病的成员携带相同CFTR变异。作者认为伴CFTR变异的患者可能对肺鸟分枝杆菌复合群病难治。
要点
- 458例肺非结核分枝杆菌病和(或)非囊性纤维化支气管扩张症患者中,16例(3.5%)检出有害CFTR变异,均为单等位基因变异。
- 与1:8年龄性别匹配的对照相比,伴CFTR变异患者痰培养转阴率更低、大环内酯类耐药率更高。
- 一个家系中患肺非结核分枝杆菌病的成员携带相同CFTR变异。
核心结论
- 作者认为伴CFTR变异的患者可能对肺鸟分枝杆菌复合群病难治。
- 需进一步全面研究评估CFTR变异对非欧洲人群肺非结核分枝杆菌病和支气管扩张症的影响。
研究设计与样本
- 单中心研究,分析2016年2月至2019年3月在庆应义塾大学医院就诊的458例肺非结核分枝杆菌病、非囊性纤维化支气管扩张症或两者兼有的患者。
- 采用外显子测序、Sanger测序和多重连接依赖探针扩增(MLPA)检测CFTR变异,并用CFTR2和计算机工具判定变异有害。
- 将有和无CFTR变异的患者按1:8年龄匹配和性别匹配进行比较。
- 对一例有肺非结核分枝杆菌病家族史患者的家系进行外显子测序。
主要发现
- 16例患者(3.5%)检出有害CFTR变异,其中1例由MLPA检出、15例由Sanger测序检出;所有患者均在一个等位基因上携带CFTR变异。
- 与匹配对照相比,伴CFTR变异患者痰培养转阴率更低、大环内酯类耐药率更高。
- 一个家系集群中,患肺非结核分枝杆菌病的成员携带相同CFTR变异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步全面研究评估CFTR变异对非欧洲人群肺非结核分枝杆菌病和支气管扩张症的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Pulmonary non-tuberculous mycobacterial (NTM) disease is a respiratory infection with an increasing incidence worldwide, including Japan. Host factors may also be involved in the establishment of pulmonary NTM disease. Cystic fibrosis transmembrane conductance regulator ( CFTR ) variants are associated with pulmonary NTM disease and bronchiectasis. However, data on CFTR variants in the Japanese population remain limited. Objectives We aimed to determine the frequency of CFTR variants and the impact on the clinical features of pulmonary NTM disease and bronchiectasis in the Japanese population. Methods We analysed 458 patients with either pulmonary NTM disease, non-cystic fibrosis bronchiectasis or both at Keio University Hospital from February 2016 to March 2019. CFTR variants were identified using exome sequencing, Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA). These variants were determined to be deleterious using CFTR2 and in silico tools. Clinical characteristics of patients with and without CFTR variants were compared in a 1:8 age-matched and sex-matched ratio. Additionally, exome sequencing was performed for the family of a patient with a family history of pulmonary NTM disease. Results Deleterious CFTR variants were identified in 16 patients (3.5%). One variant was identified by MLPA, and 15 by Sanger sequencing. All patients harboured a CFTR variant in one allele. Compared with matched controls, these patients had lower sputum culture conversion rates and higher rates of macrolide resistance. In one family cluster, members with pulmonary NTM disease were found to carry the same CFTR variant. Conclusions We defined the frequency and clinical characteristics of CFTR variants among the Japanese population with either pulmonary NTM disease, non-cystic fibrosis bronchiectasis or both and found that patients with CFTR variants may be refractory to pulmonary Mycobacterium avium complex disease. Further comprehensive research is needed to assess the impact of CFTR variants on pulmonary NTM disease and bronchiectasis in non-European populations.
引用
- BMJ Open Respiratory Research:Clinical characteristics of pulmonary non-tuberculous mycobacterial disease with CFTR variants in the Japanese population
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。